NCT00047060 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Diamandidou E, Cohen PR, Kurzrock R
Mycosis fungoides and Sezary syndrome. Blood. 1996 Oct 1;88(7):2385-409. No abstract available.
Rook AH, Heald P
The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct;9(5):997-1010.
Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM
Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000 Aug;18(15):2908-25. doi: 10.1200/JCO.2000.18.15.2908. Erratum In: J Clin Oncol 2001 Nov 1;19(21):4185.

A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H

Details for clinical trial NCT00047060

Clinical trial NCT00047060 - References